This work is licensed under a Table 3.
Subgroup baseline and delta values for subjects with serum 25(OH)D baseline values <40 nmol/L and end of study values >70 nmol/L for the vitamin D group and <40 nmol/L for the placebo group.
| Baseline | Delta values | |||
|---|---|---|---|---|
| Vitamin D | Placebo | Vitamin D | Placebo | |
| Count | 136 | 127 | 136 | 127 |
| Sex (male %) | 47.1 | 51.2 | ||
| Age (years) | 49 (41, 66) | 51 (41, 70) | ||
| Smoking (%) | 25.0 | 26.8 | ||
| Serum 25(OH)D (nmol/L) | 28.0 (6.7) | 27.9 (6.7) | 65.9 (18.7) | −1.7 (7.0) |
| BMI (kg/m2) | 27.5 (4.9) | 28.1 (4.9) | 0.16 (0.69) | 0.08 (0.69) |
| Systolic BP (mmHg) | 121 (13) | 124 (12) | −0.3 (7.6) | −0.6 (7.3) |
| Diastolic BP (mmHg) | 76 (9) | 77 (8) | 0.15 (4.6) | −0.8 (4.3) |
| Serum creatinine (μmol/L) | 70.8 (11.6) | 71.6 (11.6) | 1.0 (5.5)* | −0.3 (5.0) |
| Serum calcium (mmol/L) | 2.27 (0.07) | 2.27 (0.08) | 0.01 (0.07) | 0.0 (0.06) |
| Serum PTH (pmol/L) | 6.4 (4.0, 10.7) | 6.8 (4.3, 11.0) | −0.81 (1.34)** | 0.50 (1.57) |
| Serum triglycerides (mmol/L) | 1.20 (0.60, 2.60) | 1.20 (0.60, 2.60) | 0.00 (−0.60, 0.90) | 0.00 (−0.80, 0.70) |
| Serum cholesterol (mmol/L) | 5.27 (0.89) | 5.08 (0.93) | 0.05 (0.45) | 0.05 (0.52) |
| Serum LDL-cholesterol (mmol/L) | 3.57 (0.82) | 3.42 (0.88) | 0.06 (0.41) | 0.04 (0.46) |
| Serum HDL-cholesterol (mmol/L) | 1.40 (0.90, 2.30) | 1.30 (0.80, 2.10) | −0.01 (0.19) | 0.01 (0.15) |
| Serum apolipoprotein A1 (mmol/L) | 1.54 (0.26) | 1.47 (0.29) | −0.03 (0.15) | −0.02 (0.13) |
| Serum apolipoprotein B (mmol/L) | 1.10 (0.25) | 1.08 (0.27) | 0.04 (0.13) | 0.04 (0.13) |
| Blood glucose (mmol/L) | 5.41 (0.47) | 5.49 (0.58) | 0.04 (0.41) | −0.01 (0.38) |
| HbA1c (%) | 5.47 (0.28) | 5.49 (0.32) | 0.05 (0.15) | 0.05 (0.15) |
| Serum insulin (pmol/L) | 58 (24, 164) | 71 (25, 189) | 3.0 (−32, 54) | 2.0 (−50, 96) |
| Serum C-peptide (pmol/L) | 788 (433, 1477) | 831 (410, 1681) | 47 (198) | 11 (201) |
| Serum sRAGE (pg/mL) | 1217 (460) | 1211 (482) | 156 (274)* | 80 (300) |
| HOMA-IR | 2.31 (0.84, 7.41) | 2.89 (0.96, 8.54) | 0.15 (−1.45, 2.41) | 0.11 (−2.93, 4.18) |
Data are shown as prevalence, mean (s.d.) for normally distributed data, and median (5th, 95th percentiles) for non-normal data.
*P < 0.05, **P < 0.01 vs placebo group, linear regression with age, gender and baseline value as covariates; ***One subjects in the vitamin D and four subjects in the placebo group excluded due to change in use of blood pressure medication during the study; ****One subject in the vitamin D group excluded due to change in use of lipid lowering medication during the study.
25(OH)D, cholecalciferol; BMI, body mass index; BP, blood pressure; HbA1c, glycosylated haemoglobin; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; PTH, parathyroid hormone; sRAGE, serum human receptors for advanced glycation end products.